News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Ark Therapeutics’ Phase III Brain Cancer Drug Trial Cleared To Continue Update
January 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (AFX) - Ark Therapeutics Group PLC's final-stage trial of an experimental drug to treat brain cancer has been cleared to continue without modification, by Europe's medicine safety board.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Regulatory
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH DIA
Economic Challenges, Strategic Investments: Reshaping the Women’s Health Landscape
April 24, 2025
·
1 min read
·
Lori Ellis
Vaccines
After Missed Decision Deadline, Novavax Says COVID-19 Shot ‘Approvable’
April 24, 2025
·
2 min read
·
Tristan Manalac
Regulatory
Vanda Escalates Vendetta Against FDA, Blasts ‘Bureaucrats’ for Delaying Stomach Drug
April 24, 2025
·
2 min read
·
Tristan Manalac
Layoffs
Guessing Game: Former HHS Workers’ Next Stops Unclear
April 24, 2025
·
5 min read
·
Angela Gabriel
